Mycosubtilin | 1392-60-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: Mycosubtilin
• 英文别名: 3-[(3S,6S,13S,16R,19R,22R,25R,28S)-6,13,19,22-tetrakis(2-amino-2-oxoethyl)-16-(hydroxymethyl)-25-[(4-hydroxyphenyl)methyl]-10-(11-methyltridecyl)-2,5,8,12,15,18,21,24,27-nonaoxo-1,4,7,11,14,17,20,23,26-nonazabicyclo[26.3.0]hentriacontan-3-yl]propanamide
• CAS: 1392-60-5
• 化学式: C₅₅H₈₆N₁₄O₁₆
• 分子量: 1199.4
• InChiKey: RCIPRGNHNAEGHR-ZLHAWHIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  85
• 可旋转键数：
  26
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  509
• 氢给体数：
  15
• 氢受体数：
  16

文献信息

• PATHOGENIC BACTERIA
  申请人：Sporegen Limited

  公开号：US20200375931A1

  公开（公告）日：2020-12-03

  The present invention relates to pathogenic bacteria, and is particularly concerned with treating, preventing or ameliorating bacterial infections using novel antibiotic compositions. The invention is especially useful for treating infections of Bacillus and Clostridia species, such as Clostridium difficile, Staphylococcus aureus and Mycobacterium spp. The invention extends to pharmaceutical compositions comprising such formulations. The invention also extends to methods for identifying aerobic Bacillus spp., which exhibit antibacterial activity against other bacteria, such as C. difficile , and to methods for isolating active antibacterial compositions from these aerobic Bacillus spp.
• [EN] PATHOGENIC BACTERIA<br/>[FR] BACTÉRIES PATHOGÈNES
  申请人：SPOREGEN LTD

  公开号：WO2019162652A1

  公开（公告）日：2019-08-29

  The present invention relates to pathogenic bacteria, and is particularly concerned with treating, preventing or ameliorating bacterial infections using novel antibiotic compositions. The invention is especially useful for treating infections of Bacillus and Clostridia species, such as Clostridium difficile, Staphylococcus aureus and Mycobacterium spp. The invention extends to pharmaceutical compositions comprising such formulations. The invention also extends to methods for identifying aerobic Bacillus spp., which exhibit antibacterial activity against other bacteria, such as C. difficile, and to methods for isolating active antibacterial compositions from these aerobic Bacillus spp.